Foundation for promotion cardiology / стр. 24 из 29 / Archive / Foundation for Promotion of Cardiology

Main news

PRESS RELEASE OF THE CARDIOPROGRESS FOUNDATION

Main results of the XI International Forum

for Cardiology and Internal Medicine

ADA Advises Against Using Compounded GLP-1 RA Medications In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes.

New Trial Result Pushes Past Antiarrhythmic Therapy After MI For ventricular tachycardia after myocardial infarction, outcomes are better with upfront catheter ablation than drug therapy, which is typically used first, the multinational VANISH2 trial shows.

Editorial Activity

cardiology book

PreHT 2020|Vilnius | Lithuania | 2-5 April 2020 7th International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease (PreHT 2020)

Russian national congress of cardiology 2019

FDA Clears Architect Stat High-Sensitivity Troponin Test for MI The US Food and Drug Administration (FDA) has approved the Architect Stat (Abbott Laboratories) high-sensitivity troponin-I assay, which can detect myocardial infarction (MI) faster and more accurately than other troponin tests, according to the company.

World Heart Day 2019 This year on World Heart Day, as part of our mission to ensure heart health equity for all, we want to create a global community of Heart Heroes … people from all walks of life who are acting now to live longer, better, heart-healthy lives by making a promise: for MY HEART, for YOUR HEART, for ALL OUR HEARTS.

ESC 2019: Wrap up in Russian - Live and interactive programme In collaboration with the Russian Society of Cardiology, this programme is designed to present a selection of scientific highlights from ESC Congress and discuss clinical practice implications with experts.

ESC Congress 2019 together with World Congress of Cardiology ESC Congress 2019 together with World Congress of Cardiology Saturday 31 August - Wednesday 4 September 2019 Paris - France

Announcement of the European Congress of Cardiology From August 31 to September 4, 2019, he Congress of the European Society of Cardiology in conjunction with the World Congress of Cardiology - will be held in Paris (France).

Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).

Scientific news

New horizons of cardiotherapy Since the introduction of the first implantable stimulator and defibrillator (ICD), cardiological science has advanced far. ICDs are highly effective, but their main disadvantage is the complications associated with the electrodes. To avoid the need for venous access and complications caused by transvenous electrodes, a fully subcutaneous ICD system (pc-ICD) was developed.

Integrated model of medical care for the treatment of ST-segment elevation myocardial infarction in China A new study involving 6817 patients with acute ST-segment elevation myocardial infarction has shown that every minute of life counts. Chinese scientists have tested an integrated aid model. This study assessed the impact of a comprehensive IMPST treatment strategy in China.

The relationship between low‑density lipoprotein cholesterol, the apolipoprotein B ratio, and sarcopenia The ratio of low‑density lipoprotein cholesterol to apolipoprotein B (LDL‑C/ApoB) (LDL-C/ApoB), which reflects the cholesterol content in an atherogenic lipoprotein particle, may serve as a new biomarker for the risk of sarcopenia. Scientists conducted a study based on data from the largest American representative survey (NHANES).

Blood Pressure Variability Linked to Cognitive Decline in High-Risk Adults Higher visit-to-visit systolic blood pressure variability was independently associated with faster cognitive decline in adults at elevated cardiovascular risk, regardless of mean blood pressure levels in a study.

General Anesthesia Ups Heart Failure Risk After Valve Surgery Transcatheter aortic valve replacement (TAVR) patients who received general anesthesia had a higher incidence of heart failure at 1 year than those who received nongeneral anesthesia.

Partners

Video resource

Channel "Cardioprogress"

CARDIOPROGRESS
Foundation for the advancement of cardiology